Melatonin protects against DKD by enhancing podocyte viability, reducing oxidative stress, and suppressing NLRP3-mediated inflammation through SIRT1 upregulation. These findings highlight the potential of melatonin as a therapeutic agent for DKD.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: